低级别胶质瘤放疗后假性进展的发生率
该回顾性研究纳入2000至2011年间接受放疗的组织学确诊低级别胶质瘤患者,评估假性进展(psPD)发生率。71例中63例可评估,中位随访5年,13例(20.6%)出现psPD,中位发生时间12个月,中位持续时间6个月,且均位于至少45 Gy的放疗高剂量野内。psPD时强化面积显著小于真性进展(中位54 mm² vs 270 mm²,P=0.009)。
要点
- 低级别胶质瘤放疗后假性进展发生率为20.6%(13/63)。
- 假性进展中位发生时间12个月,中位持续时间6个月,均在放疗高剂量野内。
- 假性进展强化面积显著小于真性进展(中位54 mm² vs 270 mm²,P=0.009)。
核心结论
- 低级别胶质瘤放疗后假性进展常见,支持在进展明确前推迟新一轮治疗,尤其当患者放疗野内出现小 contrast 强化病灶时。
研究设计与样本
- 回顾性研究,纳入2000至2011年间接受放疗的组织学确诊低级别胶质瘤患者,71例中63例可评估假性进展。
主要发现
- 63例可评估患者中13例(20.6%)出现假性进展,中位随访5年(范围1-10年)。
- 假性进展中位发生时间12个月(范围3-78个月),中位持续时间6个月(范围2-26个月),均位于至少45 Gy的放疗高剂量野内。
- 假性进展时强化面积中位54 mm²(范围12-340 mm²),真性进展时中位270 mm²(范围30-3420 mm²),差异有统计学意义(P=0.009)。
关键数值与推荐
- 假性进展定义为放疗后出现新强化病灶,随后未经治疗(包括地塞米松)消失或稳定至少一年。
临床怎么用
- 作者认为,低级别胶质瘤放疗后假性进展常见,支持在进展明确前推迟新一轮治疗,尤其当患者放疗野内出现小 contrast 强化病灶时。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: As the incidence of pseudo-progressive disease (psPD), or pseudoprogression, in low-grade glioma (LGG) is unknown, we retrospectively investigated this phenomenon in a cohort of LGG patients given radiotherapy (RT). METHODS: All MRI scans and clinical data from patients with histologically proven LGG treated with radiation between 2000 and 2011 were reviewed. PsPD was scored when a new enhancing lesion occurred after RT and subsequently disappeared or remained stable for at least a year without therapy, including dexamethasone. RESULTS: Sixty-three out of 71 patients who received RT for LGG were deemed eligible for evaluation of psPD. The median follow-up was 5 years (range 1‒10 y). PsPD was seen in 13 patients (20.6%). PsPD occurred after a median of 12 months with a range of 3-78 months. The median duration of psPD was 6 months, with a range of 2-26 months and always occurred within the RT high dose fields of at least 45 Gy. The area of the enhancement at the time of psPD was significantly smaller compared with the area of enhancement during "true" progression (median size 54mm2 [range 12-340mm2] vs 270mm2 [range 30-3420mm2], respectively; P = .009). CONCLUSIONS: PsPD occurs frequently in LGG patients receiving RT. This supports the policy to postpone a new line of treatment until progression is evident, especially when patients have small contrast enhancing lesions within the RT field.
引用
- van West SE, de Bruin HG, van de Langerijt B, et al. Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. Neuro Oncol. 2017. PMID: 28453748. doi:10.1093/neuonc/now194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。